Overview

Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers

Status:
Recruiting
Trial end date:
2023-11-28
Target enrollment:
Participant gender:
Summary
This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers. Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection. Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca